TD Cowen raises target for West Pharmaceutical stock to USD 420

Published on 10/20/2026 at 14:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

TD Cowen lifted its target from USD 410 to USD 420 on October 13, 2026. West Pharmaceutical stock costs EUR 342.40 on October 20, 2026.

Quarterly growth and analyst targets

TD Cowen lifted its West Pharmaceutical target from USD 410 to USD 420 on October 13, 2026.
Second-quarter 2026 revenue reached USD 872.30 million, while adjusted earnings per share reached USD 2.37.
West Pharmaceutical stock traded at EUR 342.40 at 2:06 p.m. CEST on October 20, 2026 at Lang & Schwarz.

Reinraum-Fertigung von Vials, West Pharmaceutical, ISIN US9523901012 — West Pharmaceutical (ISIN US9523901012) stellt in sterilen Reinräumen Vials und Elastomer-Verschlüsse für Injektionssysteme her, Illustration mit AI erstellt.

West Pharmaceutical stock is trading at EUR 342.40 at Lang & Schwarz on October 20, 2026 at 2:06 p.m. CEST. TD Cowen raised its target from USD 410 to USD 420 on October 13, 2026, according to Yahoo Finance.

Why did TD Cowen raise target?

The target change adds to a positive analyst picture ahead of West's next quarterly update. MarketBeat reported that UBS raised its target from USD 340 to USD 415 on September 9, 2026, while Morgan Stanley moved its target from USD 365 to USD 400 on September 22, 2026. The same report listed an average target of USD 391.17 across its analyst coverage.

Three dates show the setup

The chronology starts on July 23, 2026, when West reported second-quarter revenue of USD 872.30 million and adjusted earnings per share of USD 2.37, as shown in the Yahoo Finance transcript. On September 9, 2026, UBS raised its target from USD 340 to USD 415. On October 13, 2026, TD Cowen raised its target from USD 410 to USD 420.

West's second-quarter revenue rose 13.80 percent year over year, while adjusted earnings per share increased 29.00 percent, according to the earnings-call transcript. Management also raised full-year 2026 adjusted earnings-per-share guidance to USD 8.85-9.05 and forecast third-quarter revenue of USD 820.00-835.00 million.

Which dates come next?

MarketBeat lists October 29, 2026, as the estimated date for third-quarter results. West's corporate website also lists a webinar on October 30, 2026, covering particulate control in parenteral drug-delivery devices.

Stock price and investor view

West makes containment and delivery products for injectable medicines and serves pharmaceutical, biotechnology, and medical-device manufacturers. Its shares trade on the New York Stock Exchange under WST and are included in the S&P 500, according to MyChesCo.

At Lang & Schwarz, West Pharmaceutical stock was trading at EUR 342.40 on October 20, 2026 at 2:06 p.m. CEST.